EGFR and non-small cell lung carcinoma: With the goal of developing a robust biomarker assay to predict prognosis in patients treated with EGFR-TKIs, we present here a ddPCR quantitative analysis of EGFR mutations (L858R, ex19del, and T790M) using cfDNA isolated from the plasma of 57 NSCLC patients.